Natera Inc

Natera Price Target Raised to $500.00/Share From $375.00 by Canaccord Genuity

Dow Jones Newswires · 5 h ago

ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology

BusinessWire · 20 h ago

Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026

BusinessWire · 4 d ago

Natera Price Target Raised to $460.00/Share From $360.00 by JP Morgan

Dow Jones Newswires · 5 d ago

Natera Is Maintained at Overweight by Morgan Stanley

Dow Jones Newswires · 6 d ago

Natera Is Maintained at Buy by TD Cowen

Dow Jones Newswires · 6 d ago

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

BusinessWire · 6 d ago

Natera, Inc. (NTRA) Partners to Enroll MRD+ CRC in Phase 2a Trial

TradingView · 6 d ago

Natera, Inc. Stock 12‑Month Price Target Raised to $387.52, Implies 3% Downside

TradingView · 7 d ago

Why Natera (NTRA) Stock Is Up Today

Stock Story · 10 d ago

Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA

dpa-AFX · 10 d ago

FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay

Reuters · 10 d ago

Natera, Inc. (NTRA) Gets FDA Breakthrough Device Tag for MCED

TradingView · 10 d ago

Natera Price Target Raised to $475.00/Share From $340.00 by Barclays

Dow Jones Newswires · 12 d ago

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

BusinessWire · 12 d ago

Natera, Inc. (NTRA) Starts Randomized Signatera-Guided Melanoma Trial

TradingView · 12 d ago

Natera Price Target Raised to $480.00/Share From $365.00 by Citigroup

Dow Jones Newswires · 13 d ago

Natera, Inc. (NTRA) Reports New Signatera Data Showing High Sensitivity in Multiple Cancers

TradingView · 13 d ago

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

BusinessWire · 13 d ago